Allogene Therapeutics (ALLO) Other Non-Current Liabilities (2018 - 2026)

Allogene Therapeutics has reported Other Non-Current Liabilities for 9 years, with the latest figure at $16.1 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 42.97% year-over-year to $16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.1 million (up 42.97% YoY) and the FY2025 annual result came in at $15.8 million, up 103.63% from the prior year.
• Other Non-Current Liabilities improved to $16.1 million in Q1 2026 per ALLO's latest filing, from $15.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $16.1 million in Q1 2026 and troughed at $5.2 million in Q1 2024.
• A 5-year average of $8.7 million and a median of $7.2 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 156.93% in 2022, then slipped 27.42% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $5.8 million in 2022, then decreased by 11.42% to $5.2 million in 2023, then surged by 49.86% to $7.8 million in 2024, then jumped by 103.63% to $15.8 million in 2025, then gained by 2.0% to $16.1 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $16.1 million, $15.8 million, and $15.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.